BioNTech COO granted options and PSUs
BioNTech SE Chief Operating Officer Sierk Poetting reported compensation-related equity grants.
Rhea-AI Filing Summary
BioNTech SE Chief Operating Officer Sierk Poetting reported compensation-related equity grants. He received 10,069 Performance Share Units and 12,586 options, each linked to ordinary shares. These awards were granted at no cash cost to him and are classified as derivative securities.
The options carry an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election. Both the options and PSUs vest annually in equal installments over four years starting on the first anniversary of the grant date and become exercisable four years after the grant date, subject to specified performance and service conditions.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 22,655 shares
Grant/Award
2 txns
Insider
Poetting Sierk
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (right to buy) | 12,586 | $0.00 | $0.00 |
| Grant/Award | Performance Share Unit | 10,069 | $0.00 | $0.00 |
Holdings After Transaction:
Option (right to buy) — 12,586 contracts (Direct);
Performance Share Unit — 10,069 contracts (Direct)
Footnotes (4)
- F1. The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.
- F2. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
- F3. The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.
- F4. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.
Key Figures
Performance Share Units granted: 10,069 units
Options granted: 12,586 options
Option exercise price: EUR 89.38 per share
+5 more
8 metrics
Performance Share Units granted
10,069 units
Grant to COO on May 12, 2026
Options granted
12,586 options
Grant to COO on May 12, 2026
Option exercise price
EUR 89.38 per share
Subject to 800% ADS price cap condition
Underlying shares for PSUs
10,069 shares
Each PSU equals one ordinary share economically
Underlying shares for options
12,586 shares
Ordinary shares underlying new options
Vesting schedule
4 annual installments
Starting on first anniversary of grant date
Exercisable after
4 years from grant
Both options and PSUs become exercisable then
Expiration date
May 12, 2036
For both options and PSUs reported
Key Terms
Performance Share Unit, American Depositary Share, Nasdaq Biotechnology Index, Option (right to buy), +1 more
5 terms
Nasdaq Biotechnology Index financial
"performance targets based on the market price ... relative to the Nasdaq Biotechnology Index"
A stock index that tracks the performance of biotechnology companies listed on the NASDAQ stock exchange, combining many firms into a single measure of the sector’s movement. Think of it as a thermometer or basket that shows whether biotech stocks are generally rising or falling; investors use it to gauge sector health, compare individual holdings against the industry, and as the basis for funds that let you invest in the whole group at once.
Option (right to buy) financial
"Option (right to buy) derivative security linked to ordinary shares"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did BioNTech (BNTX) COO Sierk Poetting receive?
Sierk Poetting received 10,069 Performance Share Units and 12,586 stock options, each tied to BioNTech ordinary shares. These are compensation grants with no cash paid at grant, designed to align his incentives with long-term share performance and service conditions.
What is the exercise price of the new BioNTech (BNTX) options?
The granted options have an exercise price of EUR 89.38 per share. The exercise price is subject to adjustment so the trading price of an American Depositary Share on an exercise date does not exceed 800% of the grant-date exercise price, according to the filing footnote.
How do the vesting terms work for BioNTech (BNTX) COO’s options and PSUs?
Both the options and PSUs vest annually in equal installments over four years, starting on the first anniversary of the grant date. They become exercisable four years after the grant date, contingent on meeting performance targets and the executive’s continued service with BioNTech through each vesting date.
How can the new BioNTech (BNTX) options be settled at exercise?
The options may be settled in ordinary shares, American Depositary Shares, and/or cash, at the election of BioNTech’s supervisory board. This flexibility allows the company to choose the settlement form while still delivering the economic value of the options to the executive upon exercise.
When do the newly granted BioNTech (BNTX) equity awards expire?
Both the options and the Performance Share Units reported have an expiration date of May 12, 2036. They vest over four years and become exercisable four years after the grant date, so any unexercised or unvested portion would lapse at that final expiration date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
